Results 1 to 10 of about 11,444 (144)

Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders [PDF]

open access: yesFrontiers in Psychiatry, 2018
Eotaxin-1/CCL11 is a chemokine originally implicated in the selective recruitment of eosinophils into inflammatory sites during allergic reactions, being thoroughly investigated in asthma, allergic rhinitis, and other eosinophil-related conditions ...
Antonio Lucio Teixeira   +2 more
exaly   +5 more sources

Structural Evidence for the Tetrameric Assembly of Chemokine CCL11 and the Glycosaminoglycan Arixtra™ [PDF]

open access: yesBiomolecules, 2013
Understanding chemokine interactions with glycosaminoglycans (GAG) is critical as these interactions have been linked to a number of inflammatory medical conditions, such as arthritis and asthma.
Julie A Leary
exaly   +7 more sources

Eotaxin-1/CCL11 is involved in cell migration in rheumatoid arthritis [PDF]

open access: yesScientific Reports, 2021
Eotaxin-1 (CCL11) induces the migration of different leukocyte types by interacting with CCR3. In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) are pathogenic effectors and a major CCR3-expressing cell.
Kuninobu Wakabayashi   +4 more
doaj   +3 more sources

Eotaxin-1 (CCL11) [PDF]

open access: yesFrontiers in Immunology, 2015
The eosinophil was first named by the brilliant German scientist Paul Ehrlich in 1879, while he was experimenting with aniline dyes to stain blood cells and tissues. He also discovered neutrophils, basophils, and mast cells. The highly basic proteins in cytosolic granules of a small subpopulation of cells in human blood stained vivid pink with the acid
TIMOTHY JOHN WILLIAMS
doaj   +4 more sources

CCL11, a novel mediator of inflammatory bone resorption [PDF]

open access: yesScientific Reports, 2017
Normal bone homeostasis, which is regulated by bone-resorbing osteoclasts and bone-forming osteoblasts is perturbed by inflammation. In chronic inflammatory disease with disturbed bone remodelling, e.g. rheumatoid arthritis, patients show increased serum
Elin Kindstedt   +5 more
doaj   +4 more sources

CCL11 promotes hepatocellular carcinoma recurrence after surgery by potentiating immunosuppressive CCR5 + CD206 + M2-like macrophages and promoting tumor invasiveness [PDF]

open access: yesCell Death and Disease
Liver resection is the primary curative treatment for early-stage hepatocellular carcinoma (HCC); however, high recurrence rates remain a major challenge in the absence of effective prognostic and preventive strategies.
Jiaqi Wang   +12 more
doaj   +2 more sources

Eotaxin-1/CCL11 promotes cellular senescence in human-derived fibroblasts through pro-oxidant and pro-inflammatory pathways

open access: yesFrontiers in Immunology, 2023
IntroductionEotaxin-1/CCL11 is a pivotal chemokine crucial for eosinophil homing to the lungs of asthmatic patients. Recent studies also suggest that CCL11 is involved in the aging process, as it is upregulated in elderly, and correlated with shorter ...
Vinicius Pierdoná, Lucas Kich Grün
exaly   +3 more sources

Eosinophils in Colorectal Neoplasms Associated with Expression of CCL11 and CCL24 [PDF]

open access: yesJournal of Pathology and Translational Medicine, 2016
Background: A decrease in the number of tissue eosinophils is known to reflect the malignancy potential of neoplastic lesions and even prognosis. Increased levels of the chemokines CCL11 and CCL24 in serum and tissue are also known to have diagnostic ...
Hyuck Cho   +6 more
doaj   +3 more sources

CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease. [PDF]

open access: yesPLoS ONE, 2017
CCL11, a protein previously associated with age-associated cognitive decline, is observed to be increased in the brain and cerebrospinal fluid (CSF) in chronic traumatic encephalopathy (CTE) compared to Alzheimer's disease (AD).
Jonathan D Cherry   +11 more
doaj   +4 more sources

C–C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease

open access: yesJHEP Reports, 2023
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is characterised by accelerated lipid deposition, aberrant inflammation, and excessive extracellular matrix production in the liver.
Huimin Liu   +2 more
exaly   +3 more sources

Home - About - Disclaimer - Privacy